Abstract

Recent candidate gene studies have identified and replicated the first associations between several common polymorphisms and pain severity in humans. Moreover, human studies in twins suggest high heritability for responses to experimental pain stimuli. Human genome-wide association studies of pain phenotypes might identify novel analgesic targets, help to prioritize research among current targets, and increase the likelihood of success for analgesic candidates emerging from animal studies. However, clinical research in pain has largely focused on small neurophysiology-based studies, so expansion of epidemiological understanding will be essential to the success of genetic or proteomic dissection of complex pain disorders. This Perspective outlines how methods of molecular epidemiology, proved effective in the study of other diseases, can enhance the returns from human genomic studies and expedite the development of new drugs to prevent or treat pain.

Author affiliations

1. Mitchell B. Max is at the Center for Pain Research, Departments of Anesthesiology and Medicine, University of Pittsburgh, A-1305 Scaife Hall, 3550 Terrace St, Pittsburgh, Pennsylvania 15261, USA.
2. Walter F. Stewart is at the Center for Health Research, Geisinger Health System, 100 N Academy Ave, Danville, Pennsylvania 17822, USA.

Correspondence to: Mitchell B. Max¹ Email: maxmb@upmc.edu

Published online 27 June 2008